Vaccine HAVRIX 720 (Child) – (2500) at Dr. Essa Lab

Vaccine HAVRIX 720 (Child) – (2500) at Dr. Essa Lab

The Vaccine HAVRIX 720 (Child) – (2500) at Dr. Essa Lab represents a critical milestone in pediatric preventive healthcare and clinical immunology. Hepatitis A is a highly contagious liver infection caused by the Hepatitis A virus (HAV), a non-enveloped RNA virus belonging to the Picornaviridae family. While the infection in young children is often mild or asymptomatic, infected pediatric patients serve as a major reservoir for the transmission of the virus to household contacts, schoolmates, and the wider community. In some cases, acute Hepatitis A can lead to severe complications, including prolonged cholestatic jaundice, relapsing hepatitis, and life-threatening acute liver failure. The Vaccine HAVRIX 720 (Child) – (2500) is an inactivated whole-virus vaccine containing the highly immunogenic HM175 strain of the Hepatitis A virus. This viral strain is propagated in human diploid cells, purified, inactivated using formaldehyde, and adsorbed onto an aluminum hydroxide adjuvant to enhance the immune response. When administered, the vaccine stimulates the child’s immune system to produce specific neutralizing antibodies (anti-HAV IgG) without introducing any live viral particles, ensuring an exceptional safety profile. Dr. Essa Lab, a premier diagnostic and preventive healthcare institution in Karachi, Pakistan, provides this essential immunization service under the highest clinical standards. By maintaining a rigorous cold-chain protocol from storage to administration, Dr. Essa Lab ensures that each vaccine dose retains its maximum potency and immunogenicity, offering robust and long-lasting protection for your child’s hepatic health.

Understanding the mechanism of active immunization is essential for appreciating the diagnostic and preventive value of the Vaccine HAVRIX 720 (Child) – (2500). Upon intramuscular injection, the inactivated viral antigens are processed by antigen-presenting cells, such as macrophages and dendritic cells. These cells present the viral epitopes to helper T-lymphocytes, which in turn activate B-lymphocytes to clonal expansion and differentiation into plasma cells. These plasma cells synthesize high-affinity immunoglobulin G (IgG) antibodies specific to the Hepatitis A virus. Additionally, memory B and T cells are generated, providing rapid and robust immune responses upon subsequent natural exposure to the virus. Clinical trials and real-world epidemiological data demonstrate that a single dose of Havrix 720 Junior induces protective antibody titers in over 95 percent of healthy children within one month of administration, while a second booster dose administered six to twelve months later ensures virtually 100 percent seroprotection lasting for several decades. By choosing Dr. Essa Lab for your child’s vaccination, you are partnering with a trusted healthcare provider committed to clinical accuracy, patient safety, and comprehensive diagnostic support.

Clinical Procedure: What to Expect

Patient Preparation

Proper preparation is key to ensuring a safe, comfortable, and effective vaccination experience for your child. Parents and guardians should follow these medically recommended guidelines before visiting Dr. Essa Lab:

• Bring Immunization Records: Always bring your child’s previous vaccination card or medical history folder. This allows the healthcare professional at Dr. Essa Lab to verify the timing of the vaccine and ensure it aligns with the recommended schedule.
• Assess Current Health Status: Ensure your child is free from moderate-to-severe acute illness or high-grade fever on the day of vaccination. A mild cold, low-grade fever, or slight cough is generally not a contraindication, but severe illness warrants postponing the injection.
• Disclose Medical History: Inform the clinician if your child has a history of severe allergic reactions (anaphylaxis) to any previous vaccine, neomycin (as trace amounts may be present), or any other substance.
• Report Bleeding Disorders: Disclose if your child has a bleeding disorder, such as hemophilia, or is taking any medications that affect blood clotting, as this requires specific injection techniques to prevent hematoma formation.
• Dress Comfortably: Dress your child in loose-fitting clothing that allows easy access to the injection site, which is typically the upper arm (deltoid muscle) for older children or the outer thigh (vastus lateralis muscle) for infants and younger toddlers.
• No Fasting Required: There are no dietary restrictions or fasting requirements. Your child should eat and drink normally before the procedure to prevent dizziness or fainting due to anxiety.

During the Procedure

The administration of the Vaccine HAVRIX 720 (Child) – (2500) at Dr. Essa Lab is conducted by highly trained pediatric nurses and medical technicians under strict aseptic conditions. The clinical process involves the following steps:

• Verification and Inspection: The healthcare professional will verify the patient’s identity, review the prescription, and inspect the vaccine vial or pre-filled syringe. They will confirm the vaccine name, pediatric dosage (0.5 mL containing 720 El.U. of viral antigen), batch number, and expiration date.
• Patient Positioning: The child will be positioned comfortably and securely. Infants and young toddlers are typically held by a parent in a comforting hug, exposing the anterolateral aspect of the thigh. Older children are seated comfortably, exposing the deltoid muscle of the non-dominant arm.
• Site Preparation: The injection site is cleansed thoroughly with an isopropyl alcohol swab using a circular motion from the center outward and allowed to air-dry completely to prevent stinging.
• Intramuscular Administration: Using a sterile, single-use needle of appropriate length, the clinician will inject the vaccine suspension deep into the muscle at a 90-degree angle. The injection is completed smoothly over a few seconds.
• Post-Injection Care: The needle is withdrawn, and gentle pressure is applied to the site with a sterile cotton ball or gauze. A small adhesive bandage may be applied. The syringe and needle are immediately disposed of in a designated sharps container.
• Observation Period: The child and parent are advised to remain in the waiting area of Dr. Essa Lab for 15 to 30 minutes post-injection. This standard safety protocol allows immediate medical management in the highly unlikely event of an acute allergic reaction or vasovagal syncope (fainting).

When is a Vaccine HAVRIX 720 (Child) – (2500) Performed?

Routine Pediatric Immunization Schedules

The Vaccine HAVRIX 720 (Child) – (2500) is primarily administered as part of routine childhood immunization schedules. Major pediatric associations and global health organizations recommend that all children receive their first dose of the Hepatitis A vaccine starting at 12 months of age. A second booster dose must be administered 6 to 12 months after the initial dose to establish long-term, sterilizing immunity. Routine vaccination during early childhood is highly effective in reducing the overall burden of Hepatitis A in the community, as young children are often the silent spreaders of the virus due to their close contact in nursery schools and daycare centers.

Travel to Hepatitis A Endemic Regions

Travel medicine specialists frequently recommend the Vaccine HAVRIX 720 (Child) – (2500) for children traveling from low-endemic countries to regions with high or intermediate rates of Hepatitis A, including parts of South Asia, Africa, Central and South America, and the Middle East. Because Pakistan is considered an endemic region, children residing here or visiting from abroad require robust protection. The vaccine should ideally be administered at least two to four weeks prior to travel to ensure that protective antibody titers have developed, although receiving the vaccine even immediately before departure still offers significant clinical benefits.

Outbreak Prevention and Post-Exposure Prophylaxis

In the event of an outbreak or known exposure to an individual with active Hepatitis A, the Vaccine HAVRIX 720 (Child) – (2500) can be administered as post-exposure prophylaxis (PEP). For unvaccinated healthy children aged 12 months and older, receiving a single dose of the vaccine within 14 days of exposure is highly effective in preventing infection or significantly reducing the severity of clinical symptoms. This rapid intervention helps contain localized outbreaks in households, schools, and residential care facilities, protecting vulnerable contacts from secondary transmission.

Children with Chronic Liver Disease or Co-morbidities

Physicians strongly advise Hepatitis A vaccination for children diagnosed with chronic liver diseases, including chronic Hepatitis B or C, biliary atresia, autoimmune hepatitis, or metabolic liver disorders. While Hepatitis A does not cause chronic liver disease itself, an acute infection superimposed on an already compromised liver can lead to catastrophic consequences, including fulminant hepatic failure and death. Immunizing these high-risk pediatric patients with Havrix 720 is a vital preventive measure to safeguard their remaining hepatic function and prevent life-threatening complications.

High-Risk Environmental Exposure Protection

Children living in areas with compromised water sanitation, overcrowded housing, or those attending specialized boarding schools and daycares are at an elevated risk of fecal-oral transmission of pathogens. In such environments, the risk of waterborne or foodborne transmission of the Hepatitis A virus is significantly higher. Administering the Vaccine HAVRIX 720 (Child) – (2500) provides a robust immunological shield, ensuring that even if a child is exposed to contaminated water or food, their immune system can neutralize the virus immediately, preventing clinical illness and local transmission.

What Does a Vaccine HAVRIX 720 (Child) – (2500) Detect?

While the Vaccine HAVRIX 720 (Child) – (2500) is a preventive immunization rather than a diagnostic test, its administration directly influences, prevents, and modulates several clinical markers, physiological pathways, and pathological findings. The primary clinical outcomes, preventive detections, and physiological parameters associated with this vaccine include:

• Stimulation of Anti-HAV IgG Antibodies: Detects the successful transition from immunological naivety to active immunity through the presence of protective immunoglobulin G antibodies in post-vaccination serology.
• Prevention of Acute Hepatocyte Necrosis: Prevents the direct viral invasion and subsequent immune-mediated destruction of liver cells (hepatocytes).
• Prevention of Elevated Alanine Aminotransferase (ALT): Prevents the leakage of this intracellular hepatic enzyme into the bloodstream, maintaining normal serum ALT levels.
• Prevention of Elevated Aspartate Aminotransferase (AST): Prevents acute liver injury that typically causes marked elevations in serum AST levels during active infection.
• Prevention of Hyperbilirubinemia: Prevents the accumulation of bilirubin in the blood, thereby avoiding clinical jaundice (yellowing of the skin and sclera).
• Prevention of Cholestasis: Prevents the inflammation of bile canaliculi, ensuring normal bile flow and preventing elevated alkaline phosphatase (ALP) levels.
• Prevention of Prolonged Prothrombin Time (PT/INR): Safeguards the liver’s synthetic function, ensuring normal production of coagulation factors and maintaining a healthy INR.
• Prevention of Viral Replication in Hepatic Parenchyma: Prevents the Hepatitis A virus from establishing a replication cycle within the liver tissue.
• Prevention of Viral Shedding in Feces: Eliminates the excretion of active viral particles in stool, thereby halting the fecal-oral transmission chain.
• Prevention of Acute Liver Failure (Fulminant Hepatitis): Eliminates the risk of rapid, catastrophic liver failure requiring emergency transplantation.
• Prevention of Hepatomegaly: Prevents painful liver enlargement and right upper quadrant abdominal tenderness.
• Prevention of Splenomegaly: Prevents secondary splenic enlargement associated with systemic viral infections and portal congestion.
• Prevention of Systemic Viral Prodrome: Prevents the onset of fever, severe malaise, myalgia, and generalized fatigue.
• Prevention of Gastrointestinal Distress: Prevents severe nausea, persistent vomiting, and anorexia (loss of appetite) in children.
• Prevention of Bilirubinuria: Prevents the excretion of conjugated bilirubin in urine, avoiding the characteristic dark, tea-colored urine.
• Prevention of Acholic Stools: Prevents the development of pale, clay-colored stools caused by biliary obstruction during active infection.
• Prevention of Relapsing Hepatitis: Prevents the clinical phenomenon where symptoms recur weeks after apparent recovery from natural infection.
• Prevention of Cholestatic Hepatitis Syndrome: Prevents prolonged pruritus (itching) and jaundice associated with atypical cholestatic variants.
• Prevention of Secondary Family Outbreaks: Protects household members by ensuring the vaccinated child does not become an infectious vector.
• Maintenance of Normal Serum Albumin: Protects the liver’s capacity to synthesize essential plasma proteins.
• Prevention of Pediatric Hospitalization: Reduces the clinical and financial burden of emergency medical admissions due to dehydration or liver complications.
• Establishment of Decades-Long Immunological Memory: Ensures the persistence of memory B and T lymphocytes for long-term surveillance.

Turnaround Time and Report Access at Dr. Essa Lab

At Dr. Essa Lab, the documentation and reporting process for vaccinations are designed to be seamless, efficient, and highly accessible for parents. Immediately following the administration of the Vaccine HAVRIX 720 (Child) – (2500), the clinical staff will update your child’s physical immunization card. This card is stamped and signed, detailing the exact date of administration, the vaccine brand (Havrix 720 Junior), the manufacturer (GSK), the batch or lot number, and the scheduled date for the second booster dose (if applicable). This physical record is vital for school admissions, international travel, and future medical consultations.

In addition to the physical card, Dr. Essa Lab utilizes an advanced electronic medical record (EMR) system. The vaccination details are instantly uploaded to the secure online database. Parents can access this digital immunization certificate at any time through the official Dr. Essa Lab web portal or mobile application. If a physician requests a post-vaccination serology test (such as a quantitative Anti-HAV IgG antibody test) to confirm successful seroconversion, the blood sample is processed in Dr. Essa Lab’s state-of-the-art immunology department. The turnaround time for such serological reports is typically 24 to 48 hours, with results delivered directly to your smartphone via SMS or email, ensuring maximum convenience and peace of mind.

Vaccine HAVRIX 720 (Child) – (2500) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Anti-HAV IgG Antibodies	Positive (Post-Vaccination, indicating active immunity)	Negative (Post-Vaccination, indicating non-response or pre-vaccination state)
Serum Alanine Aminotransferase (ALT)	7 to 56 U/L (Normal hepatic function)	Markedly elevated (>1000 U/L in acute Hepatitis A infection)
Serum Aspartate Aminotransferase (AST)	10 to 40 U/L (Normal hepatic function)	Markedly elevated in acute hepatocellular injury
Total Serum Bilirubin	0.2 to 1.2 mg/dL (No clinical jaundice)	Elevated (>2.5 mg/dL, causing yellowing of skin and eyes)
Prothrombin Time (PT/INR)	INR approximately 1.0 (Normal coagulation profile)	Prolonged INR (>1.5, indicating severe hepatic synthetic dysfunction)
Fecal HAV Antigen / RNA	Negative (No active viral shedding)	Positive (Active viral shedding and high infectivity)
Clinical Liver Palpation	Soft, non-tender, normal size for age	Hepatomegaly (enlarged, tender liver under the right rib cage)
Systemic Symptoms	Absent (Healthy, active child)	Fever, dark urine, pale stools, severe lethargy, and vomiting

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Vaccine HAVRIX 720 (Child) – (2500)?

• Strict Cold-Chain Management: Dr. Essa Lab maintains an uninterrupted, temperature-controlled cold chain from vaccine receipt to administration, ensuring maximum potency and efficacy of the Havrix 720 vaccine.
• Qualified Pediatric Professionals: Vaccinations are administered by certified nurses and medical technicians who specialize in pediatric care, ensuring a gentle and stress-free experience for children.
• ISO Certified Laboratories: Dr. Essa Lab adheres to international standards of quality, safety, and hygiene, minimizing any risk of cross-contamination or infection.
• Comprehensive Digital Records: Parents receive instant digital updates and can access their child’s complete immunization history anytime via the secure online portal or mobile app.
• Extensive Branch Network: Conveniently located across Karachi and other major cities, making it easy to access quality healthcare close to home.
• Trusted Legacy of Excellence: Serving the community since 1987, Dr. Essa Lab is a household name trusted by generations of families and leading physicians.
• Safe and Sterile Environment: Strict adherence to infection control protocols, sterile single-use equipment, and clean, comfortable clinical spaces.
• Holistic Family Healthcare: Offers a complete range of diagnostic, preventive, and wellness services, allowing you to manage your family’s health under one trusted roof.